1. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study. (21st January 2022) Authors: Sallette, M; Bouhnik, Y; Nachury, M; Bellanger, C; Laharie, D; Amiot, A; Peyrin-Biroulet, L; Roblin, X; Altwegg, R; Buisson, A; Reenaers, C; Bouguen, G; Vuitton, L; Bourreille, A; Gilletta, C; Serrero, M; Hébuterne, X; Filippi, J Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i084 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P361 Risk of persistent gastrointestinal inflammation after treatment with immune checkpoint inhibitors. (30th January 2023) Authors: Jeay, M; Carbonnel, F; Robert, C; Bellanger, C; Meyer, A Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P474 Efficacy and safety of anti-TNF and vedolizumab in liver transplant recipients with inflammatory bowel disease (IBD). (16th January 2018) Authors: Bellanger, C; Beaugerie, L; Amiot, A; Tezenas du Montcel, S; Duvoux, C; Samuel, D; Carbonnel, F Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗